Succeeder(SH:688338) Sou Hu Cai Jing·2025-05-21 05:44Core Viewpoint - The company Saikehde has experienced a decline in revenue and net profit in the first quarter of 2025, while its stock price has shown a slight increase, indicating potential challenges in the medical device industry despite a relatively low PE ratio compared to industry averages [1][2]. Company Summary - Saikehde's stock closed at 24.45 yuan, up 1.12%, with a rolling PE ratio of 24.55, marking a 30-day low. The total market capitalization is 2.595 billion yuan [1]. - The company operates in the field of thrombus and hemostasis in vitro diagnostic instruments, reagents, and consumables, with key products including automated testing devices and various coagulation testing instruments [1]. - As of March 31, 2025, the number of shareholders increased to 6,725, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]. - The latest financial report for Q1 2025 shows revenue of 68.6393 million yuan, a year-on-year decrease of 9.47%, and a net profit of 23.1329 million yuan, down 23.98%, with a gross margin of 62.49% [1]. Industry Summary - The average PE ratio for the medical device industry is 49.51, with a median of 36.17, positioning Saikehde at the 56th rank within the industry [2]. - The industry average market capitalization is 10.636 billion yuan, indicating that Saikehde's market cap is significantly lower than the industry average [2].